Literature DB >> 26929274

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Guillaume Olombel1, Estelle Guerin1, Julien Guy2, Jean-Yves Perrot3, Florent Dumezy4, Adrienne de Labarthe5, Jean-Noël Bastie6, Ollivier Legrand7, Emmanuel Raffoux5, Adriana Plesa8, Orianne Wagner-Ballon9, Edouard Cornet10, Véronique Salaun10, Claude Preudhomme4, Xavier Thomas11, Cécile Pautas12, Sylvain Chantepie13, Pascal Turlure14, Sylvie Castaigne15, Hervé Dombret5, Jean Feuillard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26929274     DOI： 10.1182/blood-2016-01-689976

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  28 in total

1.  Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.

Authors:  Johann Hitzler; Elihu Estey
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

2.  Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.

Authors:  George S Laszlo; Mary E Beddoe; Colin D Godwin; Olivia M Bates; Chelsea J Gudgeon; Kimberly H Harrington; Roland B Walter
Journal:  Haematologica       Date:  2018-08-16       Impact factor: 9.941

Review 3.  Antibody-Based Treatment of Acute Myeloid Leukemia.

Authors:  Phillip M Garfin; Eric J Feldman
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 4.  [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors:  Ni-Na Wang; Qi-Dong Ye
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

Review 5.  Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

Authors:  Jeffrey Baron; Eunice S Wang
Journal:  Expert Rev Clin Pharmacol       Date:  2018-06-11       Impact factor: 5.045

Review 6.  Gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  C D Godwin; R P Gale; R B Walter
Journal:  Leukemia       Date:  2017-06-13       Impact factor: 11.528

Review 7.  Biological and clinical consequences of NPM1 mutations in AML.

Authors:  E M Heath; S M Chan; M D Minden; T Murphy; L I Shlush; A D Schimmer
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

Review 8.  The clinical development of antibody-drug conjugates - lessons from leukaemia.

Authors:  Elias Jabbour; Shilpa Paul; Hagop Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2021-03-23       Impact factor: 66.675

9.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jatinder K Lamba; Lata Chauhan; Miyoung Shin; Michael R Loken; Jessica A Pollard; Yi-Cheng Wang; Rhonda E Ries; Richard Aplenc; Betsy A Hirsch; Susana C Raimondi; Roland B Walter; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2017-06-23       Impact factor: 44.544

10.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.